Oncology Imaging

Cancer contributed to 7.6 million deaths worldwide in 2008, and was linked with nearly 170 million years of healthy life lost, according to a study published online Oct. 16 in The Lancet.

Physicians view active surveillance for prostate cancer as effective for managing low-risk prostate cancer, but few recommend the strategy, according to results of a national survey presented Oct. 12 at the North Central American Urological Association Meeting.

For relatively small lung nodules, low-dose unenhanced CT significantly underestimates volume, increasing the risk that malignant growth rates will be missed at follow-up, according to a study published in the October issue of the American Journal of Roentgenology.

Researchers at Kansas State University have developed a blood test that can, in roughly one hour, detect the beginning stages of cancer.

Twelve genetic markers have been associated with the development of erectile dysfunction following radiation therapy (RT) for prostate cancer, according to a study published online Sept. 27 in the International International Journal of Radiation Oncology• Biology• Physics.

Prostate cancer is at the core of contentious clinical, economic and policy debates. As researchers, policymakers, physicians and payers attempt to revise the script for prostate cancer management the process may offer lessons that can be applied across the healthcare continuum.

September may be my favorite month of the year. The hot, muggy days of August have ceased, replaced by fresh fall air with just the right nip of cool on most days. Backpacks are full, dorm rooms are decorated and school buses prowl the streets as parents and kids anticipate a new school year and fresh start.

Lung cancer is usually detected at an advanced stage. Attempts at demonstrating the benefits of screening and early detection had been elusive, until the results of the National Lung Screening Trial (NSLT), sponsored by the National Cancer Institute, were published in the New England Journal of Medicine on Aug. 4, 2011.

Interventional oncology techniques are gaining traction with liver and prostate cancers, particularly when other therapies have not proven successful. However, redirecting the tide of conventional treatment represents a significant obstacle.

Clinical studies have proven that screening for certain cancers and heart disease saves lives. But questions linger. Will those screened derive any mortality benefit? If so, how great is it? What is the cost relative to gains, relative to treatment costs? This month were drilling down into CT screening, for lung cancer, colorectal cancer and coronary artery disease. There are still more questions than answers, but studies are underway.